CN1771033A - 应用atii拮抗剂治疗或预防代谢综合征 - Google Patents

应用atii拮抗剂治疗或预防代谢综合征 Download PDF

Info

Publication number
CN1771033A
CN1771033A CNA2004800093941A CN200480009394A CN1771033A CN 1771033 A CN1771033 A CN 1771033A CN A2004800093941 A CNA2004800093941 A CN A2004800093941A CN 200480009394 A CN200480009394 A CN 200480009394A CN 1771033 A CN1771033 A CN 1771033A
Authority
CN
China
Prior art keywords
receptor antagonist
angiotensin
type
treatment
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800093941A
Other languages
English (en)
Chinese (zh)
Inventor
A·荣格伦
A·斯文斯森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1771033A publication Critical patent/CN1771033A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800093941A 2003-04-03 2004-03-31 应用atii拮抗剂治疗或预防代谢综合征 Pending CN1771033A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use
SE03009883 2003-04-03

Publications (1)

Publication Number Publication Date
CN1771033A true CN1771033A (zh) 2006-05-10

Family

ID=20290927

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800093941A Pending CN1771033A (zh) 2003-04-03 2004-03-31 应用atii拮抗剂治疗或预防代谢综合征

Country Status (15)

Country Link
US (1) US20060194856A1 (https=)
EP (1) EP1613309A1 (https=)
JP (1) JP2006522115A (https=)
KR (1) KR20050114671A (https=)
CN (1) CN1771033A (https=)
AU (1) AU2004226517B2 (https=)
BR (1) BRPI0408979A (https=)
CA (1) CA2520960A1 (https=)
IL (1) IL170706A0 (https=)
MX (1) MXPA05010660A (https=)
NO (1) NO20054370L (https=)
NZ (1) NZ542640A (https=)
SE (1) SE0300988D0 (https=)
WO (1) WO2004087136A1 (https=)
ZA (1) ZA200507945B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080132555A1 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
US20150051220A1 (en) * 2012-03-16 2015-02-19 Glucox Biotech Ab Compounds for use in therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
HUP0301335A3 (en) * 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
KR101092279B1 (ko) * 2002-12-27 2011-12-13 다케다 야쿠힌 고교 가부시키가이샤 체중 증가 억제제

Also Published As

Publication number Publication date
EP1613309A1 (en) 2006-01-11
KR20050114671A (ko) 2005-12-06
NO20054370D0 (no) 2005-09-21
IL170706A0 (en) 2009-02-11
JP2006522115A (ja) 2006-09-28
BRPI0408979A (pt) 2006-04-04
NZ542640A (en) 2008-06-30
WO2004087136A1 (en) 2004-10-14
MXPA05010660A (es) 2005-12-12
AU2004226517B2 (en) 2008-01-24
SE0300988D0 (sv) 2003-04-03
AU2004226517A1 (en) 2004-10-14
CA2520960A1 (en) 2004-10-14
ZA200507945B (en) 2007-04-25
NO20054370L (no) 2005-10-31
US20060194856A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
CN1234357C (zh) 缬沙坦和钙通道阻断剂的抗超敏组合
Mann Management of heart failure patients with reduced ejection fraction
JP2010536880A (ja) 糖尿病の合併症のための療法
DK2420231T3 (en) Angiotensin-II receptor antagonist for the treatment of cardiovascular disease in cats.
CN107296810A (zh) 心舒宁在治疗肥厚型心肌病（hcm）中的应用
JP2023001352A (ja) アルカリ性化剤による血液浄化
EP1017376A4 (en) PROCESS FOR TREATING HEART FAILURE
CN1771033A (zh) 应用atii拮抗剂治疗或预防代谢综合征
CN101584700A (zh) 一种药物组合物
US20200179369A1 (en) Treatment of diabetic nephropathy
JP5974056B2 (ja) インスリン耐性を有する前糖尿病患者における２型糖尿病およびその合併症の予防に有用な組成物
US8569381B2 (en) Combination therapy for the management of hypertension
CN1298389C (zh) 一种含替米沙坦和钙离子拮抗剂的复方降压制剂及其应用
WO2014034871A1 (ja) 脂質異常症の予防又は治療薬
RU2616522C2 (ru) Фармацевтическая композиция для профилактики или лечения гиперлипидемии
JP2008514689A (ja) Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用
CN1827170A (zh) 含有二氢吡啶类钙拮抗剂和苯氧芳酸类药物的组合物
EA049529B1 (ru) Фармацевтическая композиция, содержащая арни и антагонист ионов кальция, и ее применение
Aksnes et al. Impact of diabetes development on atrial fibrillation in hypertensive patients.
Fogari et al. DIFFERENCE IN INCIDENCE OF COUGH INDUCED BY IMIDAPRIL AND RAMIPRIL: ROLE OF PROSTAGLANDIN SYNTHESIS INHIBITION: PP. 33.312
Efanov et al. ARTERIAL HYPERTENSION CONTROL IN THE EXTREME NORTH POPULATION OF THE EMPLOYABLE AGE: PP. 34.397
JPWO2005117855A1 (ja) 糖尿病の予防または治療のための薬剤
JPWO2005112944A1 (ja) 糖尿病の予防または治療のための薬剤
WO2007032536A1 (ja) 脂質・糖代謝性疾患の治療剤としてのヒスタミンh3アゴニスト

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060510